Scarica l'app Stockscreener
209.84
0.88%
1.83
Dopo l'orario di chiusura:
209.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$208.01
Aprire:
$210.81
Volume 24 ore:
751.49K
Relative Volume:
0.78
Capitalizzazione di mercato:
$14.77B
Reddito:
$2.71B
Utile/perdita netta:
$247.10M
Rapporto P/E:
59.94
EPS:
3.5008
Flusso di cassa netto:
$349.90M
1 W Prestazione:
-6.94%
1M Prestazione:
-14.91%
6M Prestazione:
-32.03%
1 anno Prestazione:
-20.09%
Intervallo 1D:
$206.55
$212.92
Intervallo di 1 settimana:
$205.11
$227.24
Portata 52W:
$205.11
$354.88
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
209.84 | 14.64B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Winners And Losers Of Q4: Insulet (NASDAQ:PODD) Vs The Rest Of The Patient Monitoring Stocks - finance.yahoo.com
Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD - MarketBeat
Insulet (NASDAQ:PODD) Reaches New 12-Month LowTime to Sell? - MarketBeat
Insulet Earnings: Stellar Finish to 2025 With Strong Fourth Quarter - Morningstar
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insulet Corporation (PODD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement - MSN
Insulet Corp. Stock Hits New 52-Week Low at USD 215.26 - Markets Mojo
Consumer safety roundup: Major recalls affect Einstein Bros., Insulet, Amneal and Falcon Trading - washingtontimes.com
Insulet Corp (PODD) Shares Down 4.53% on Mar 30 - GuruFocus
Is Insulet’s (PODD) New CCO Hire a Subtle Reset of Its Global Commercial Strategy? - simplywall.st
Insulet names Mike Panos as chief commercial officer By Investing.com - Investing.com Canada
Insulet Corporation Appoints Mike Panos as Executive Vice President and Chief Commercial Officer, Effective March 30, 2026 - marketscreener.com
Insulet names Mike Panos as chief commercial officer - Investing.com
Insulet Appoints Mike Panos as Chief Commercial Officer - Bakersfield.com
Insulet Reports Improved EVOLUTION 2C Trial Outcomes - Let's Data Science
SG Americas Securities LLC Purchases 36,570 Shares of Insulet Corporation $PODD - MarketBeat
Beacon Investment Advisory Services Inc. Cuts Position in Insulet Corporation $PODD - MarketBeat
Insulet recalling certain defective Omnipod insulin delivery devices - MSN
PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm - Business Wire
Is Insulet stock underperforming the Dow? - MSN
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know - finance.yahoo.com
2026-03-27 | Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PODD | Press Release - Stockhouse
Vanguard (PODD) parent reports 0 shares after realignment; subsidiaries to report - Stock Titan
Insulet (PODD) down 8.2% since last earnings report: Can it rebound? - MSN
Jayme Wilson joins Brunson, Insulet Corporation hires Cameron Yung, Ashley Csanady promoted at McMillan Vantage - ipolitics.ca
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insulet Corporation (PODD) And Encourages Investors to Connect - ACCESS Newswire
Insulet Trials Closed Loop Pod For Type 2 Diabetes As Shares Lag - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - PR Newswire
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Insulet Corporation (PODD) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Insulet Corporation stock hits 52-week low at $216.12 By Investing.com - Investing.com India
Insulet stock hits 52-week low amid Omnipod 5 defect probe and class action scrutiny - AD HOC NEWS
Published on: 2026-03-26 06:50:47 - baoquankhu1.vn
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
Insulet (NASDAQ:PODD) Hits New 12-Month LowShould You Sell? - MarketBeat
Insulet stock faces securities fraud probe pressure after Omnipod 5 pod recall and sharp NASDAQ decl - AD HOC NEWS
Insulet slides as investors weigh Omnipod 5 device correction and potential 2026 costs - quiverquant.com
Insulet Corporation stock hits 52-week low at $216.12 - Investing.com
Is Insulet (PODD) Pricing Reflect Its Recent Share Pullback And DCF Implied Upside Potential - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insulet Corporation (PODD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Diversified Trust Co. Purchases 6,742 Shares of Insulet Corporation $PODD - MarketBeat
Assenagon Asset Management S.A. Buys 24,761 Shares of Insulet Corporation $PODD - MarketBeat
Insulet stock faces pressure amid investor probe and recent share pullback on NASDAQ - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ... - Bluefield Daily Telegraph
Omnipod Recall Lawsuit - AboutLawsuits.com
Insulet OmniPod 5 Recall Lawsuits May Be Filed Over Problems Resulting in Diabetic Ketoacidosis, Hospitalization and Death - AboutLawsuits.com
PODD SEC FilingsInsulet Corp 10-K, 10-Q, 8-K Forms - Stock Titan
M & L Capital Management Ltd Purchases Shares of 5,630 Insulet Corporation $PODD - MarketBeat
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insulet Corporation Azioni (PODD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McEvoy Ashley | President and CEO |
Feb 20 '26 |
Buy |
239.35 |
4,300 |
1,029,205 |
13,916 |
| Frederick Wayne A.I. | Director |
Dec 15 '25 |
Sale |
293.09 |
1,851 |
542,510 |
2,158 |
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):